Please use this identifier to cite or link to this item: http://buratest.brunel.ac.uk/handle/2438/10123
Title: Levonorgestrel-releasing intrauterine system vs. usual medical treatment for menorrhagia: An economic evaluation alongside a randomised controlled trial
Authors: Sanghera, S
Roberts, TE
Barton, P
Frew, E
Daniels, J
Middleton, L
Gennard, L
Kai, J
Gupta, JK
Keywords: economic evaluation;Levonorgestrel-releasing intrauterine device ('LNG-IUS')
Issue Date: 2014
Publisher: Public Library of Science
Citation: PLoS ONE, 9:3, 2014
Abstract: Objective: To undertake an economic evaluation alongside the largest randomised controlled trial comparing Levonorgestrel-releasing intrauterine device ('LNG-IUS') and usual medical treatment for women with menorrhagia in primary care; and compare the cost-effectiveness findings using two alternative measures of quality of life. Methods: 571 women with menorrhagia from 63 UK centres were randomised between February 2005 and July 2009. Women were randomised to having a LNG-IUS fitted, or usual medical treatment, after discussing with their general practitioner their contraceptive needs or desire to avoid hormonal treatment. The treatment was specified prior to randomisation. For the economic evaluation we developed a state transition (Markov) model with a 24 month follow-up. The model structure was informed by the trial women's pathway and clinical experts. The economic evaluation adopted a UK National Health Service perspective and was based on an outcome of incremental cost per Quality Adjusted Life Year (QALY) estimated using both EQ-5D and SF-6D. Results: Using EQ-5D, LNG-IUS was the most cost-effective treatment for menorrhagia. LNG-IUS costs £100 more than usual medical treatment but generated 0.07 more QALYs. The incremental cost-effectiveness ratio for LNG-IUS compared to usual medical treatment was £1600 per additional QALY. Using SF-6D, usual medical treatment was the most cost-effective treatment. Usual medical treatment was both less costly (£100) and generated 0.002 more QALYs. Conclusion: Impact on quality of life is the primary indicator of treatment success in menorrhagia. However, the most costeffective treatment differs depending on the quality of life measure used to estimate the QALY. Under UK guidelines LNG-IUS would be the recommended treatment for menorrhagia. This study demonstrates that the appropriate valuation of outcomes in menorrhagia is crucial. Copyright: © 2014 Sanghera et al.
URI: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0091891
http://bura.brunel.ac.uk/handle/2438/10123
DOI: http://dx.doi.org/10.1371/journal.pone.0091891
ISSN: 1932-6203
Appears in Collections:Health Economics Research Group (HERG)

Files in This Item:
File Description SizeFormat 
Fulltext.pdf986.56 kBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.